t is no secret that the population of the United States is getting bigger-and not just more people, but more pounds per person as well. In fact, more than 60%, or about 100 million people, are overweight, and half of these are obese, [1] [2] [3] which increases risk for diabetes, cardiovascular disease, and some cancers. 3 Furthermore, it is becoming increasingly clear that psychiatric disorders and their treatments also impact these same health factors. And the news is not good. Diabetes in particular may be even more common in patients with schizophrenia and bipolar disorder than in the general population. 4 Add to that the potential for some psychotropic drugs to increase weight and the incidence of diabetes, 5 and it seems obvious that psychopharmacologists should now be on the lookout for The Metabolic Syndrome (Table 1) 6 in their clinical practices, since they are in a powerful position to recognize and treat this syndrome as well as possibly cause or worsen it.
What is The Metabolic Syndrome and Can Psychotropic Drugs Contribute to It?
The hallmark of The Metabolic Syndrome, or Syndrome X, is the presence of insulin resistance associated with a cluster of metabolic abnormalities independent of whether the individual develops type 2 diabetes or not.
7 It is well known that an individual with a vulnerable genetic makeup and excessive caloric intake, high fat ingestion, and decreased physical activity can become obese and develop insulin resistance. Numerous psychotropic drugs are widely recognized to be factors in weight gain, and, ultimately, obesity. 5, 8 What is only now being uncovered by case reports and pharmacoepidemiologic studies is the association of various atypical antipsychotics with hyperglycemia, new onset of type 2 diabetes, and occasionally ketoacidosis due to a mechanism not completely explained by weight gain. 5, 8 Whether one drug or another is more likely to cause these adverse effects is greatly debated, and the field eagerly awaits the results of definitive prospective randomized studies of sufficient power to tell us the answer.
Monitoring and Managing the Risks in Psychopharmacology
In the meantime, there should be no debate that well-established risk factors have already been identified 6 (Table 2) and that the time has come for prescribers of a broad range of psychoactive drugs to begin to monitor (Table 3) and manage (Table 4) these risk factors in their practices.
The natural history of type 2 diabetes begins with the development of insulin resistance, with compensatory hyperinsulinemia, which is at first sufficient to overcome the insulin re-
sistance and maintain normal glucose tolerance. It then proceeds to a 50% loss of beta cell function, with loss of compensatory hyperinsulinemia, and then postprandial hyperglycemia. Eventually, patients may become sufficiently insulin deficient that they need exogenous insulin. This progressive metabolic disturbance is well known to be associated with increased risk for cardiovascular disease, 6 so identifying at-risk individuals and doing our best to reduce these risk factors while we are prescribing psychotropic drugs is now the state of the art for psychopharmacology practice. The interventionist psychopharmacologist should also treat or refer for treatment patients who have obesity or hyperglycemia, and should know their baseline metabolic status to assess whether adding drugs to treat psychiatric disorders will push the at-risk patient over the edge from normal weight to overweight, from overweight to obesity, or from normoglycemia to hyperglycemia and type 2 diabetes. Refer patients with abnormal glucose or lipid levels for medical consultation Do your best to encourage weight loss, since even modest weight loss can have health benefits Leverage your therapeutic rapport to establish moderate exercise and discourage smoking proactively whenever possible Be alert to the possibility of diabetic ketoacidosis, especially in diabetic patients newly begun on atypical antipsychotics Consider discontinuing the antipsychotic, because it may resolve hyperglycemia and diabetes in some cases
